KAP1 (7C5) Monoclonal Antibody

Flow cytometric analysis of HeLa cells with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

$Lane 1: HepG2 Cells; Lane 2: Hela Cells; Probed with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: HepG2 Cells; Lane 2: Hela Cells; Probed with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human lung cancer tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human lung cancer tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human liver cancer tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human liver cancer tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human spleen tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human spleen tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human kidney tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human kidney tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse brain tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse brain tissue incubated with KAP1 (7C5) Monoclonal Antibody (bsm-52679R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
FCM
IHC-P
IF(ICC)
IHC

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-52679R
Product Name	KAP1 (7C5) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(ICC), IHC
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	N terminus human KAP1
Clonality	Monoclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20C for 12 months.
Target
Gene ID	10155
Swiss Prot	Q13263
Synonyms	Transcription intermediary factor 1-beta, E3 SUMO-protein ligase TRIM28, KRAB-associated protein 1, KRAB-interacting protein 1, Nuclear corepressor KAP-1, RING finger protein 96, Tripartite motif-containing protein 28, TIF1-beta, KAP-1, KRIP-1, TRIM28
Background	Nuclear corepressor for KRAB domain-containing zinc finger proteins (KRAB-ZFPs). Mediates gene silencing by recruiting CHD3, a subunit of the nucleosome remodeling and deacetylation (NuRD) complex, and SETDB1 (which specifically methylates histone H3 at 'Lys-9' (H3K9me)) to the promoter regions of KRAB target genes. Enhances transcriptional repression by coordinating the increase in H3K9me, the decrease in histone H3 'Lys-9 and 'Lys-14' acetylation (H3K9ac and H3K14ac, respectively) and the disposition of HP1 proteins to silence gene expression. Recruitment of SETDB1 induces heterochromatinization. May play a role as a coactivator for CEBPB and NR3C1 in the transcriptional activation of ORM1. Also corepressor for ERBB4. Inhibits E2F1 activity by stimulating E2F1-HDAC1 complex formation and inhibiting E2F1 acetylation. May serve as a partial backup to prevent E2F1-mediated apoptosis in the absence of RB1. Important regulator of CDKN1A/p21(CIP1). Has E3 SUMO-protein ligase activity toward itself via its PHD-type zinc finger. Also specifically sumoylates IRF7, thereby inhibiting its transactivation activity. Ubiquitinates p53/TP53 leading to its proteosomal degradation; the function is enhanced by MAGEC2 and MAGEA2, and possibly MAGEA3 and MAGEA6. Mediates the nuclear localization of KOX1, ZNF268 and ZNF300 transcription factors.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC